Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose Tamoxifen. | Synapse
February 10, 2026
Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose Tamoxifen.
Key Points
The aim is to evaluate adherence to endocrine prevention using low-dose tamoxifen in women with atypical hyperplasia and lobular carcinoma in situ.
Analyzed real-world data on medication adherence.
Focused on women using low-dose tamoxifen.
Monitored side effects and reasons for discontinuation.
High adherence rates observed among women who started medication.
Few patients discontinued treatment due to side effects.
Abstract
Adherence to endocrine prevention is high in women who initiate medication, with few discontinuing due to side effects.